Classes
DEA Class; Rx
Common Brand Names; Neupro
- Antiparkinson Agents, Dopamine Agonists
Description
Non-ergoline dopamine agonist; transdermal patch formulation
Used for early and advanced Parkinson’s disease and restless legs syndrome
May cause abrupt onset of sleep or excessive drowsiness resulting in serious harm
Indications
Indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease.
Contraindications
Hypersensitivity
Adverse Effects
- Nausea (34-48%)
- Application site reactions (including erythema, pruritus, irritation, burning, dermatitis, inflammation, papulae, vesicle, pain) (21-46%)
- Dizziness (14-22%)
- Somnolence (12-20%)
- Vomiting (10-20%)
- Fatigue (6-18%)
- Insomnia (5-11%)
- Hyperhidrosis (3-11%)
- Application site reactions (36-46%)
- Somnolence (32%)
- Nausea (22-28%)
- Dizziness (14-23%)
- Dyskinesia (14-17%)
- Edema peripheral (9-14%)
- Insomnia (9-14%)
- Hallucinations (7-14%)
- Arthralgia (8-11%)
- Application site reactions (23-43%)
- Nausea (15-23%)
- Headache (15-21%)
- Asthenia (7-14%)
Warnings
Patients with Parkinson disease or RLS may experience new or worsening mental status and behavioral changes; these may include sudden onset of sleep while engaging in activities of daily living, consider dose reduction or discontinuation of treatment if patient develops compulsive behavior
Pregnancy and Lactation
There are no adequate data on developmental risk associated with use in pregnant women
There are no data on presence of drug in human milk, effects on the breastfed infant, or on milk production; however, inhibition of lactation may occur because drug decreases secretion of prolactin in humans; studies have shown that rotigotine and/or its metabolite(s) are excreted in rat milk
Maximum Dosage
8 mg/24 hours transdermally for PD; 3 mg/24 hr transdermally for RLS.
8 mg/24 hours transdermally for PD; 3 mg/24 hr transdermally for RLS.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Rotigotine
transdermal patch
- 1mg/24 hr
- 2mg/24 hr
- 3mg/24 hr
- 4mg/24 hr
- 6mg/24 hr
- 8mg/24 hr
